Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

96.64 -0.17 (-0.18%)
Official Closing Price Updated: 7:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
Ozempic Supply Is Running Low: Here's Why That Can Be A Problem
Ozempic, the diabetes drug also used as a so-called "miracle" weight-loss drug, has been sweeping through America and is now in limited supply. 
Via Benzinga
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
Viatris now faces a narrower path to commercializing a generic copy of Ozempic. 
Via The Motley Fool
Novo Nordisk Unusual Options Activity For October 30
Via Benzinga
Can Diabetes, Weight-Loss Drugs Get Even Better?
Via Investor Brand Network
Looking At Novo Nordisk's Recent Unusual Options Activity
Via Benzinga
Can Diabetes, Weight-Loss Drugs Get Even Better?
EQNX::TICKER_START (NASDAQ:LEXX,NYSE:NVO:NYSE:PFE,NYSE:MRK,NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Novo Nordisk Just Consolidated Its Grip on Yet Another Market. Is It a Buy?
Novo Nordisk is planting the seeds to become a competitor in chronic kidney disease therapies. 
Via The Motley Fool
Benzinga Bulls And Bears: Tesla, Chevron, Eli Lilly And Dogecoin Co-founder's 3 Favorite Cryptos
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
(NVO) - Analyzing Novo Nordisk's Short Interest
Via Benzinga
1 Green Flag and 1 Red Flag for Novo Nordisk
Even this high-flying company has its detractors. 
Via The Motley Fool
Is Ozempic Killing Liposuction? A Stock That Could Get Hit Hard From New Weight-Loss Drugs
Ozempic, Novo Nordisk’s (NYSE: NVO) diabetes drug, is now popular for weight loss. The rise of the drug could become a major headwind for other companies that provide weight-loss services such... 
Via Benzinga
Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?
Makers of devices to treat obesity-related conditions have struggled recently. Analysts say there's more to the story. 
Via Investor's Business Daily
3 Monster Buy-and-Hold Growth Stocks to Buy Right Now for $1K
These are three growth stocks you will want to buy and never sell if you have $1,000 available to invest today. 
Via InvestorPlace
Weight Loss Drugs Like Wegovy Would Not Impact Business - Healthcare Companies Tell Investors
Novo Nordisk A/S (NYSE: NVO) investors and analysts eagerly await the company's third-quarter results, hoping for clarity on when supply limitations for its weight-loss drug, Wegovy, in the U.S.  
Via Benzinga
Q3 Earnings Season Scorecard - Earnings Growth Turns Positive
The Q3 revenue beats percentage of 63.2% is the lowest since the 61.7% for this group of companies in 2020 Q1. 
Via Talk Markets
Weight Loss Drugs Wegovy, Ozempic Gain Traction With Millennials, High Earners: New Survey Results
A new survey reveals the consumer segments showing the greatest interest in weight loss medications such as Ozempic, Mounjaro, and Wegovy. 
Via Benzinga
Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027
EQNX::TICKER_START (OTCPK:CNER),(NYSE:NVO),(NASDAQ:TNDM),(NASDAQ:DXCM),(NASDAQ:LXRX) EQNX::TICKER_END 
Via FinancialNewsMedia
Demand for Ozempic and Wegovy Is Through the Roof. Here's Why it Can Go Even Higher.
Employers could help bolster demand for weight-loss treatments. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
2 Historically Cheap Dow Dividend Kings That Are Ripe for the Picking
These inexpensive Dow components have achieved royalty status among income stocks -- more than 60 consecutive years of dividend increases. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Top Consumer Staples Stocks to Buy In Q4
Consumer staples stocks aren’t having a good year after delivering record gains in 2022. Here are three to buy for a rebound in 2024. 
Via InvestorPlace
Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield...
The upcoming quarter GDP is expected to hit 3.7% which has brought the FED dialogue to “higher rates for longer” which might lead us to a recession in 2024. So watch the yield on the 10-year TSY now at... 
Via Talk Markets
Topics Economy
Exposures Economy
3 Stocks to Buy From the ‘Buy the Dip’ ETF
It’s a lot harder than it looks to buy the dip. Using artificial intelligence to do this makes these three stocks a buy. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Healthcare Stocks to Invest in for a Big Shot of Gains
While healthcare stocks are down for the most part this year, there are a few names that offer the promise of big future profits. 
Via InvestorPlace
2 Stock-Split Stocks That Could Plunge Up to 89%, According to Select Wall Street Analysts
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are two high-flying stock-split stocks a pair of analysts believe will lose their... 
Via The Motley Fool
3 Unstoppable Stocks to Buy Sooner Rather Than Later
Now is the time to invest in these great stocks. 
Via The Motley Fool
Is Your Weight-loss Medication Genuine? Demand For Drugs From Novo Nordisk And Eli Lilly Leads To Surge In Counterfeits
As obesity rates climb worldwide, so does the demand 
Via Benzinga
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin... 
Via Talk Markets
This Stock-Split Stock Is Beating Both Apple and Microsoft in 2023 -- With No Artificial Intelligence (AI) Tailwind at All
This big pharma stock has been a big winner, thanks to two blockbuster drugs. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.